Gemcitabine plus cisplatin vs gemcitabine plus carboplatin in patients with adva nced non-small-cell lung cancer
- VernacularTitle:吉西他滨联合顺铂或卡铂治疗晚期非小细胞肺癌的近期疗效
- Author:
Ping YU
;
Ping CHENG
;
Li LIAO
- Publication Type:Journal Article
- Keywords:
lung neoplasm;
advanced non-small-cell lung c ancer;
gemcitabine;
cisplatin;
carboplatin;
drug therapy
- From:
China Oncology
2000;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To study the efficacy and toxicity of g emcitabine/cisplatin(GP) and gemcitabine/carboplatin(GC) in patients with advanc ed non-small-cell lung cancer(NSCLC). Methods:patients for GP: gemcitabine 1 000 mg/m 2,days 1 a nd 8 plus cisplatin 30 mg/m 2 days 1-3 or GC:gemcitabine 1 000 mg/m 2 , days 1 and 8 plus carboplatin AUC=5 day 1. Cycles were repeated every 3 weeks. Results:54 patients to GP and 52 to GC. The objective response rate(CR+PR)was 48.1% for GP and 44.2% for GC. No significant differences between arms were observed in response rate. No significant differences between arms we re observed in median time to progression(6.8 months GP, 6.2 months GC).GP arm h ad a remarkably higher incidence of grade nausea/vomiting Ⅲ-Ⅳ than GC arm(P
